Compare AbbVie Inc (ABBV) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Kyndryl Holdings Inc — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Kyndryl Holdings Inc trades at $12 (market cap $2.73B). The key difference: AbbVie Inc is far larger — about 164.8× Kyndryl Holdings Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals.
| ABBV | KD | |
|---|---|---|
Market Cap | $449.91B | $2.73B |
Sector | Health | Technology |
52-Week High | $261.07 | $43.38 |
52-Week Low | $184.85 | $10.59 |
Enterprise Value | $513.38B | $5.07B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
Kyndryl Holdings (KD) trades at $12.39, up 1.14% on the day, with a bullish technical signal from moving averages. The company reported revenue of $15.06B for 2025, achieving a net income of $252M, marking a return to profitability after losses in prior years. Recent news includes a partnership with Microsoft for sovereignty solutions and new executive appointments, but also legal investigations into the company's disclosures following a significant stock price decline earlier in 2026.
The outlook is mixed; improving cash flow and a low EV/EBITDA of 3.19 suggest undervaluation, but recent earnings misses and legal overhangs pose risks. Analyst consensus is a 'Hold' with a $14.33 price target, implying modest upside. Key investor focus is on the Q2 2026 earnings report due August 5, 2026, for confirmation of the profitability turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
